Vienna, 14.12.2022. After many years as a shareholder of Shield Therapeutics plc, AOP Health has become the company's principal equity investor.
Through a commercial partnership with the global healthcare company Viatris Inc, a convertible loan from AOP Health, and the recently completed equity raise, Shield Therapeutics plc has raised a total of $33 million, which will be used to expand its commercial effectiveness including a significant expansion of field, digital and direct to consumer marketing. This will enable a significant further increase of sales of Accrufer® in the US. AOP Health has participated in the capital raise at its current ownership percentage.
Andreas Steiner, Group Chief Executive Officer of AOP Health International Management AG: "AOP Health accompanies and supports Shield Therapeutics as we believe in the potential of its lead product, Accrufer® (USA) or Feraccru® (Europe), a non-salt-based oral therapy for iron deficiency in adults. We are therefore supporting the company's next important step, the expansion in the U.S. market."
Together with Viatris and enabled by AOP Health’s capital and equity boost, Shield Therapeutics expects to significantly increase sales in the U.S. market.